WUGEN Presents New Data for Key CAR-T Platform at the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR

Thursday, February 21, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Presentations feature new preclinical data on WUGEN's core fratricide-resistant CAR-T therapy platform targeting T-cell malignancies

ST. LOUIS, Feb. 20, 2019 /PRNewswire/ -- WUGEN Inc., a biotechnology company developing a novel, universal allogeneic

CAR-T therapy platform, today announced data presentations at the 2019 Transplantation & Cellular Therapy (TCT) Meetings of ASBMT and CIBMTR, Feb. 20 – 24 in Houston. New data will be presented on WUGEN's core platform technology supporting its "off-the-shelf," fratricide-resistant CAR-T cell therapy for T-cell malignancies.

"We are driving innovation in CAR-T therapies with our novel technology platform," said John McKearn, Ph.D., CEO of WUGEN. "Our preclinical data validate the use of allogeneic 'off-the-shelf' adoptive immunotherapy for the treatment of Sézary syndrome, bringing hope to an underserved patient population. These findings will allow us to advance our understanding of CAR-T therapies to improve patient outcomes."

Presentations:

Title: A Long-Acting Pharmacological Grade Interleukin-7 Molecule Logarithmically Accelerates CART Proliferation, Differentiation, and Tumor Killing (Abstract #223) Presented: Matt L. Cooper, Ph.D., Washington University of St. Louis Date/Time: Wednesday, Feb. 20 at 6:45 p.m. CST Location: George R. Brown Convention Center, Hall B3

Title: Modeling Sézary Syndrome for Immunophenotyping and Anti-Tumor Effect of Ucart and Long-Acting Interleukin-7 Combination Therapy (Abstract #228) Presented: Karl W. Staser, Ph.D., Washington University of St. Louis Date/Time: Wednesday, Feb. 20 at 6:45 p.m. CST Location: George R. Brown Convention Center, Hall B3

Title: CS1 Targeted Chimeric Antigen Receptors (CAR) for Treatment of Multiple Myeloma (Abstract #579) Presented: Julie O'Neal, Ph.D., Washington University of St. Louis Date/Time: Saturday, Feb. 23 at 6:45 p.m. CST Location: George R. Brown Convention Center, Hall B3

About WUGEN

WUGEN Inc., is a biotechnology company developing a novel CAR-T therapy platform including an "off-the-shelf" fratricide-resistant CAR-T cell therapy for T-cell malignancies. WUGEN's state-of-the-art gene editing technologies and cutting-edge CAR-T cell therapy address some of the challenges that have limited the clinical development of allogeneic CAR-T cells. WUGEN was founded based on technology licensed from Washington University in St. Louis. For more information please visit www.wugen.com. 

For media inquiries contact: David Schull or Travis KruseRusso Partners858-717-2310212-845-4272david.schull@russopartnersllc.com travis.kruse@russopartnersllc.com

Cision View original content:http://www.prnewswire.com/news-releases/wugen-presents-new-data-for-key-car-t-platform-at-the-2019-transplantation--cellular-therapy-meetings-of-asbmt-and-cibmtr-300799182.html

SOURCE WUGEN Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store